Literature DB >> 26160192

A mutation spectrum that includes GNAS, KRAS and TP53 may be shared by mucinous neoplasms of the appendix.

Kieko Hara1, Tsuyoshi Saito2, Takuo Hayashi1, Alkam Yimit1, Michiko Takahashi1, Keiko Mitani1, Makoto Takahashi3, Takashi Yao1.   

Abstract

Appendiceal mucinous tumors (AMTs) are classified as low-grade appendiceal mucinous neoplasms (LAMNs) or mucinous adenocarcinomas (MACs), although their carcinogenesis is not well understood. As somatic activating mutations of GNAS are considered to be characteristic of LAMNs while TP53 mutations have been shown to be specific to MACs, MACs are unlikely to result from transformation of LAMNs. However, emerging evidence also shows the presence of GNAS mutations in MACs. We examined 16 AMTs (11 LAMNs and 5 MACs) for genetic alterations of GNAS, KRAS, BRAF, TP53, CTNNB1, and TERT promoter in order to elucidate the possibility of a shared genetic background in the two tumor types. Extensive histological examination revealed the presence of a low-grade component in all cases of MAC. GNAS mutations were detected in two LAMNs and in one MAC, although the GNAS mutation in this MAC was a nonsense mutation (Q227X) expected not to be activating mutation. TP53 mutations were detected in three LAMNs; they were frequently detected in MACs. KRAS mutations were detected in three LAMNs and three MACs, and CTNNB1 mutations were detected in two LAMNs. KRAS mutation and activating mutation of GNAS occurred exclusively in AMTs. BRAF and TERT mutations were not detected. Overexpression of p53 was observed in only two MACs, and p53 immunostaining clearly discriminated the high-grade lesion from a low-grade component in one. These findings suggest that p53 overexpression plays an important role in the carcinogenesis of AMTs and that, in addition to mutations of GNAS, KRAS and TP53 alterations might be shared by AMTs, thus providing evidence for the possible progression of LAMNs to MAC.
Copyright © 2015 Elsevier GmbH. All rights reserved.

Entities:  

Keywords:  Appendiceal mucinous neoplasm; GNAS; KRAS; Mismatch repair gene; Mutation; TP53

Mesh:

Substances:

Year:  2015        PMID: 26160192     DOI: 10.1016/j.prp.2015.06.004

Source DB:  PubMed          Journal:  Pathol Res Pract        ISSN: 0344-0338            Impact factor:   3.250


  9 in total

1.  GNAS mutations in primary mucinous and non-mucinous lung adenocarcinomas.

Authors:  Lauren L Ritterhouse; Marina Vivero; Mari Mino-Kenudson; Lynette M Sholl; A John Iafrate; Valentina Nardi; Fei Dong
Journal:  Mod Pathol       Date:  2017-08-04       Impact factor: 7.842

Review 2.  Omics analyses in peritoneal metastasis-utility in the management of peritoneal metastases from colorectal cancer and pseudomyxoma peritonei: a narrative review.

Authors:  Christin Lund-Andersen; Annette Torgunrud; Karianne Giller Fleten; Kjersti Flatmark
Journal:  J Gastrointest Oncol       Date:  2021-04

3.  ASO Author Reflections: Establishing Novel Molecular Subtypes of Appendiceal Cancer.

Authors:  Mary Garland-Kledzik; Adam Khader; Diego M Marzese
Journal:  Ann Surg Oncol       Date:  2021-10-27       Impact factor: 5.344

4.  Diffuse expression of MUC6 defines a distinct clinicopathological subset of pulmonary invasive mucinous adenocarcinoma.

Authors:  Satsuki Kishikawa; Takuo Hayashi; Tsuyoshi Saito; Kazuya Takamochi; Shinji Kohsaka; Kei Sano; Noriko Sasahara; Keita Sasa; Taisei Kurihara; Kieko Hara; Yoshiyuki Suehara; Fumiyuki Takahashi; Kenji Suzuki; Takashi Yao
Journal:  Mod Pathol       Date:  2020-10-06       Impact factor: 7.842

5.  Molecular profiling of appendiceal serrated lesions, polyps and mucinous neoplasms: a single-centre experience.

Authors:  Giada Munari; Gianluca Businello; Paola Mattiolo; Angelo Paolo Dei Tos; Matteo Fassan; Gianmaria Pennelli; Marta Sbaraglia; Chiara Borga; Salvatore Pucciarelli; Gaya Spolverato; Claudia Mescoli; Francesca Galuppini; Antonio Sommariva; Elena Bellan; Sara Lonardi; Fotios Loupakis; Claudio Luchini
Journal:  J Cancer Res Clin Oncol       Date:  2021-03-12       Impact factor: 4.553

6.  The role of mucin cell-free DNA detection as a new marker for the study of acellular pseudomyxoma peritonei of appendicular origin by liquid biopsy.

Authors:  Damián García-Olmo; Susana Olmedillas-López; Delia Cortés-Guiral; Pedro Villarejo; Irene López Rojo; Héctor Guadalajara; Soledad García Gómez-Heras; Mariano García-Arranz
Journal:  Ther Adv Med Oncol       Date:  2020-06-24       Impact factor: 8.168

7.  Clinical Benefit from Trametinib in a Patient with Appendiceal Adenocarcinoma with a GNAS R201H Mutation.

Authors:  Celina Ang; Aryeh Stollman; Hongfa Zhu; Umut Sarpel; Bethann Scarborough; Gagan Sahni; Sherri Z Millis
Journal:  Case Rep Oncol       Date:  2017-06-22

8.  The curious case of Gαs gain-of-function in neoplasia.

Authors:  Giulio Innamorati; Thomas M Wilkie; Havish S Kantheti; Maria Teresa Valenti; Luca Dalle Carbonare; Luca Giacomello; Marco Parenti; Davide Melisi; Claudio Bassi
Journal:  BMC Cancer       Date:  2018-03-15       Impact factor: 4.430

9.  Autoantibody to GNAS in Early Detection of Hepatocellular Carcinoma: A Large-Scale Sample Study Combined with Verification in Serial Sera from HCC Patients.

Authors:  Xiao Wang; Keyan Wang; Cuipeng Qiu; Bofei Wang; Xiaojun Zhang; Yangcheng Ma; Liping Dai; Jian-Ying Zhang
Journal:  Biomedicines       Date:  2022-01-04
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.